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Running title: Urinary complement proteins in IgAN 
 
Abstract 
Aim: Complement activation is involved in the pathogenesis and progression of IgA 
nephropathy (IgAN); however, the clinical implication of abnormal complement protein levels in 
serum and urine is not clear. To address this we analysed the correlation between disease 
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activity and complement proteins in serum and urine from IgAN patients, and compared to 
patients with other types of chronic kidney disease (CKD) as well as healthy controls.  
  
Methods: We included 85 Chinese patients with IgAN, 23 patients with non-proliferative CKD, 
and 20 healthy individuals. Patients were divided according to the Oxford classification of 
M0E0S0T0 (group 1, n= 20), M1E1S0-1T0-1 (group 2, n=25), M1E1S0-1T2 or M0E0S1T1-2 
(group 3, n=40). Complement factor H (CFH), mannose-binding lectin (MBL) and membrane 
attack complex (MAC; C5b-9) in serum and urine were measured by enzyme-linked 
immunosorbent assay.  
 
Results: Urinary CFH, C5b-9 and serum CFH were increased in both IgAN and CKD patients 
compared with healthy controls. The urinary excretion of CFH was the highest in IgAN patients 
with most tubulointerstitial damage (IgAN group 3). Urinary CFH and MBL levels were 
significantly higher in IgAN patients with crescents formation (C1-2) than in patients without (C0). 
Urinary complement protein excretion correlated negatively with estimated glomerular filtration 
rate, and positively with urinary retinol-binding protein and α1-microglobulin excretion indicating 
proximal tubule dysfunction.  
 
Conclusion: Increased urinary excretion of complement proteins in IgAN is related to chronic 
injury and tubular dysfunction. This warrants caution using urinary complement proteins as 
markers of disease activity. 
 
Key words: Chronic kidney disease, complement proteins, IgA nephropathy, proximal tubule 
dysfunction, urinary. 
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Introduction 
IgA nephropathy (IgAN) is the most common, primary glomerulonephritis worldwide, leading to 
end-stage renal disease (ESRD) in up to 40% of patients within 10-20 years.1 Although it has 
been over 40 years since its recognition, the pathogenic mechanisms of IgAN are still unclear. 
Accumulating evidence indicates that complement activation is involved in the pathogenesis and 
development of IgAN.2,3 Specifically, C3 mesangial co-deposition with IgA1 is the major 
histopathological feature of IgAN,2,4 and properdin,5 C4 or C4d,6 as well as the membrane attack 
complex (MAC; C5b-9)7 are also frequently detected in renal biopsies. These findings suggest 
activation of complement system, especially alternative and lectin pathway, participating in the 
pathological changes of this disease.  
 
Complement factor H (CFH) is one of the most important inhibitory proteins of the alternative 
pathway by competing with C3 convertase and by acting as a cofactor for factor I in the C3b 
cleavage.8 Mannose-binding lectin (MBL) is a liver derived C-type lectin, which activates the 
complement cascade by recognizing carbohydrates on the surfaces of many pathogens 
followed by reaction with MBL-associated serine proteases MASP-1 and MASP-2.9,10 Several 
studies have demonstrated deposition of both CFH11,12 and MBL10,13 in glomeruli as well as their 
correlations to the disease severity of IgAN. Recently, a significant elevation of both CFH and 
MBL in urine from patients with IgAN was observed to be associated with prognosis.12,14,15 Yet, 
the clinical implication of these complement proteins in urine has not been fully elucidated. 
 
The present study sought out to investigate the association between serum and urinary CFH, 
MBL, complement activation marker C5b-9 and disease severity of IgAN. We measured the 
levels of CFH, MBL and C5b-9 in serum and urine from IgAN patients with different 
histopathological phenotypes based on Oxford classification as well as the patients with chronic 
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kidney disease (CKD) owing to non-proliferative disease. We analysed the association between 
these complement proteins in serum and urine and clinical as well as histopathological 
parameters in IgAN patients. In addition, we evaluated the association between proximal tubule 
damage markers, retinol-binding protein (RBP) and α1-microglobulin (α1-MG), and urinary 
complement protein excretion in patients with IgAN.  
 
Methods 
Patients and samples 
A total of 85 Chinese patients with IgAN confirmed by kidney biopsy and fulfilling the 
histopathologic criteria of Oxford classification M0E0S0T0, M1E1S0-1T0-1, M1E1S0-1T2, or   
M0E0S1T1-2 were enrolled in this cross-sectional study between December 2014 and 
November 2017 at the First Affiliated Hospital of Zhengzhou University, China. Patients treated 
with immunosuppressive agents, including prednisone, at the time of kidney biopsy, or with 
other coexisting renal pathology or recurrent IgAN after kidney transplantation were excluded. 
Twenty-three patients with biopsy-proven focal segmental glomerulosclerosis (FSGS, n = 9) or 
hypertensive nephrosclerosis (n = 14) were included as non-proliferative CKD controls and 
twenty age- and sex-matched healthy individuals were as healthy controls. The study was 
approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University, China 
and was conducted in accordance with the Declaration of Helsinki. Written informed consent 
was obtained from all participants prior to their inclusion in this study.  
 
Clinical data including age, gender, mean arterial pressure (MAP), serum creatinine, 24-hour 
urinary protein, and medication were recorded at the time of kidney biopsy. The estimated 
glomerular filtration rate (eGFR) was estimated using the CKD-EPI formula.16 Early-morning 
fasting blood and urine samples for assessment of the complement proteins were collected from 
all included patients on the morning of kidney biopsy. The blood and urine samples were 
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centrifuged at 2000g and 600g, respectively, for 10 minutes and the sediment was discarded; 
the supernatant was immediately frozen at −80°C until further analysis.  
 
Histological assessment 
For histopathology, sections were routinely stained with haematoxylin and eosin (HE), periodic-
acid Schiff (PAS), Masson, periodic-acid-silver methenamine (PASM) and immunofluorescence 
at the Department of Renal Pathology at the First Affiliated Hospital of Zhengzhou University. 
Two pathologists who were blinded to patients’ data examined the sections. The 
histopathological changes in the renal biopsy were graded based on the Oxford classification.17 
Accordingly, the included patients were stratified into three groups: 1) M0E0S0T0 representing 
minimal damage (n=20, group 1); 2) M1E1S0-1T0-1 representing proliferative changes (n=25, 
group 2) and 3) M1E1S0-1T2 or M0E0S1T1-2 representing sclerotic damage (n=40, group 3). 
Well-defined cellular or fibrocellular crescents, but not fibrous crescents, were included in the 
crescent score: C0 equal to no crescents, C1 equal to crescents in less than one fourth of 
glomeruli, and C2 equal to crescents in over one fourth of glomeruli as described previously.18,19 
The intensity of staining for C3 was scored as follows: 0, invisible; 1, ambiguous under a low-
power lens and apparent under a high-power lens; 2, apparent under a low-power lens and 
clear under a high-power lens; 3, clear under a low-power lens and bright under a high-power 
lens.20  
 
ELISA analysis and biochemical tests 
Serum and urinary levels of CFH (Abcam, Cambridge, UK), MBL (CUSABIO, Wuhan, China) 
and C5b-9 (CUSABIO) were measured using commercially available ELISA kits according to 
the manufacturer’ procedure. The absorbance at 450nm was recorded using a microplate 
reader (EMax Plus, Molecular Devices, Sunnyvale, CA, USA). Each sample was performed in 
2-3 replicates with low intra-assay and inter-assay coefficient of variations (%CV < 10-15). The 
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ratios of urinary CFH, MBL or C5b-9 concentration to creatinine concentration (ng/mg) were 
calculated and used for analyses, respectively. 
 
Serum creatinine and urinary total protein, creatinine, RBP and α1-MG were measured using an 
automatic biochemical analyzer in the Clinical Laboratory Center at the First Affiliated Hospital 
of Zhengzhou University. Specifically, RBP was measured by Immune Turbidimetry (YIJIE 
Biology, Ningbo, China) and α1-MG was measured by Latex Turbidimetry (YIJIE Biology). The 
ratio of urinary RBP (α1-MG) concentration to creatinine concentration (µg/mg) was calculated 
and used for the analyses. 
 
Statistical analysis 
Continuous data are presented as mean ± SD or median (lower and upper quartiles) while 
categorical data are presented as absolute frequencies and percentages. Chi-square test was 
used to compare categorical variables. For normally distributed data, the T-test was used to 
compare between two groups. Non-normally distributed data set were compared using the 
Mann-Whitney U-test or Kruskal-Wallis test. The Bonferroni method was applied to correct for 
multiple comparisons. The correlations among various parameters were analysed using 
Pearson or Spearman’s coefficient. Data with a skewed distribution (urinary CFH, MBL and 
C5b-9) were logarithmic transformed to make these conform or close to a normal distribution. A 
P-value of less than 0.05 was considered statistically significant. Data were analysed using the 
SPSS v.19.0 software (IBM Corp., Armonk, NY, USA). 
 
Results  
Demographic and clinical data of all subjects 
Demographic and clinical data of the healthy controls, CKD patients and IgAN patients are 
summarized in Table 1. No significant differences in age, gender, and use of renin-angiotensin 
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system-blockade were observed between groups. All IgAN patients, including three subgroups, 
and the CKD patients had significantly higher MAP and 24-hour urinary protein levels when 
compared with healthy controls, and MAP was higher in IgAN patients of group 3 than in group 
1. The serum creatinine levels were higher and eGFR lower in all IgAN patients, including the 
patients in subgroup 2 and 3, as well as in CKD patients when compared to healthy controls. 
The IgAN patients of group 3 had significantly higher levels of serum creatinine and lower eGFR 
as compared with group 1 and 2. Serum creatinine levels and eGFR were normal and 
comparable to healthy controls in IgAN patients of group 1. 
 
Serum CFH, MBL and C5b-9 levels in IgAN and controls 
Serum CFH levels were significantly increased and MBL levels decreased in IgAN patients, 
including all three subgroups, as well as in CKD patients when compared with healthy controls 
(Figure 1A and 1B). Serum C5b-9 levels in IgAN patients were significantly higher than in 
healthy controls; when these patients were divided into subgroups, this difference was only 
significant in group 3 (Figure 1C). No significant differences in serum CFH, MBL, or C5b-9 were 
observed between IgAN subgroups (Figure 1). 
 
Urinary CFH, MBL and C5b-9 levels in IgAN and controls 
Urinary CFH levels were significantly higher in IgAN patients, including all subgroups, as well as 
in CKD patients when compared to healthy controls (Figure 2A). Moreover, IgAN patients of 
group 3 showed higher levels of urinary CFH than group 1 and 2 (Figure 2A). Patients with IgAN, 
including all subgroups, revealed higher levels of urinary MBL compared to healthy controls 
(Figure 2B). When combined, all IgAN patients, as well as the patients in group 3 revealed 
significantly higher levels of urinary MBL than the CKD patients (Figure 2B). Urinary C5b-9 
levels were also higher in IgAN patients and in CKD patients compared to healthy controls; 
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however, when IgAN patients were divided into subgroups, this difference was only significant 
for group 3 (Figure 2C).  
 
Thus, IgAN is associated with increased serum CFH and C5b-9, decreased serum MBL, as well 
as increased urinary excretion of all three complement proteins when compared to healthy 
controls. The same pattern was observed for CKD patients with non-proliferative disease except 
that these patients did not have significantly elevated serum C5b-9 and urinary MBL. There 
were no correlations between the levels of these complement proteins in urine and respective 
levels in serum from patients with IgAN (Figure S1).  
 
Serum and urinary complement proteins, and crescent score in IgAN 
The percentage of IgAN patients with crescents (C1-2) was significantly higher in both group 2 
and 3 when compared to group 1 (Table 2), and patients with crescents (C1-2) had a lower 
eGFR than patients without (C0; 63.59 ± 35.52 versus 84.97 ± 39.08 ml/min/1.73m2, P = 0.01). 
There was no significant difference in the glomerular deposition of C3 between IgAN subgroups 
(Table 2), or between the patients with C0 and C1-2 (data not shown). The serum CFH levels 
were significantly decreased in IgAN patients with C1-2 compared with the patients with C0 
(1.12 [0.9, 1.5] versus 1.42 [1.13, 1.76] mg/ml, P = 0.02), while IgAN patients with C1-2 had 
significantly higher levels of urinary CFH and MBL than the patients with C0 (CFH/Cr: 220.49 
[113.26, 375.42] versus 128.56 [67.62, 216.1] ng/mg, P = 0.007; MBL/Cr: 6.28 [2.44, 17.72] 
versus 3.06 [1.62, 5.82] ng/mg, P = 0.02). There were no significant differences in the levels of 
serum MBL, serum C5b-9 or urinary C5b-9 between the two groups (data not shown).  
 
Correlations between urinary complement proteins, eGFR and proteinuria in IgAN  
Urinary CFH, MBL and C5b-9 levels correlated inversely with eGFR in patients with IgAN 
(Figure 3A). The 24-hour urinary protein excretion significantly correlated with urinary CFH, but 
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not with urinary MBL or C5b-9 (Figure 3B). The findings show that in patients with IgAN the 
urinary excretion of complement proteins CFH, MBL and C5b-9 is associated with renal function 
(eGFR) while the correlation with total proteinuria is weak (CFH only). In patients with CKD no 
significant correlations were observed between urinary excretion of all three complement 
proteins and eGFR (Figure 3C). However, urinary CFH and MBL, but not C5b-9 correlated 
positively with 24-hour urinary protein excretion (Figure 3D).  
 
Correlations between urinary complement proteins and markers of proximal tubule 
dysfunction 
The urinary excretion of both RBP (Figure 4A-4C) and α1-MG (Figure 4D-4F) correlated 
significantly and positively with the urinary excretion of CFH, MBL and C5b-9, but negatively 
with eGFR in patients with IgAN (Figure S2). A similar, positive correlation of urinary CFH, MBL 
and C5b-9 with the two tubular damage markers was observed in CKD patients (Table 3). Both 
RBP and α1-MG are freely filtered in the glomerulus and reabsorbed by megalin, which is highly 
expressed in proximal tubule and serves as a scavenger for proximal tubule uptake of filtered 
proteins.21-23 Thus, urinary excretion of RBP and α1-MG may be considered markers of proximal 
tubule dysfunction. Together, the findings support the notion that the increased urinary excretion 
of these complement proteins correlates with proximal tubule dysfunction, and possible megalin 
dysfunction, in both IgAN and CKD. 
 
Discussion 
The present study shows 1) that IgAN is associated with increased levels of serum CFH and 
C5b-9 as well as decreased levels of serum MBL compared to healthy controls; however, 
similar changes in serum CFH and MBL were observed in CKD patients; 2) the levels of 
complement proteins (except MBL) in urine from both IgAN patients and CKD patients were 
higher than in healthy controls; 3) urinary CFH and MBL levels were significantly higher in IgAN 
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patients with crescent formation than in the patients without; and 4) the urinary complement 
protein excretion correlated inversely with eGFR and was strongly associated with tubular 
damage markers (RBP and α1-MG) in patients with IgAN.  
 
Complement activation has been associated with the pathogenesis of IgAN as part of the four-
hit model: Increased circulating levels of galactose-deficient IgA1 (Hit 1) followed by synthesis 
and binding of antibodies directed against galactose-deficient IgA1 which form immune 
complexes accumulating in the glomerular mesangium (Hits 2 and 3), and finally activation of 
mesangial cells inducing proliferation and secretion of inflammatory mediators (Hit 4).2,24  
Complement is activated, mainly via alternative and lectin pathway,2 by the deposition of 
immune complexes and by the activation of mesangial cells, which eventually contributes to 
kidney tissue damage. CFH and MBL are important complement proteins associated with the 
alternative or lectin pathway. Previous studies have demonstrated elevated levels of urinary 
CFH, MBL and C5b-9 correlating with the degree of renal damage, suggesting that complement 
activation may occur within the urinary space; in line with this, it has been proposed that urinary 
complement components could be useful biomarkers of kidney injury in IgAN.12,14,15,25 However, 
no direct comparison with other types of kidney injury has been performed and the concomitant 
analysis of complement proteins in serum was not included. 
 
We found that serum and urinary levels of CFH and urinary levels of C5b-9 were increased in 
both IgAN patients and other CKD patients when compared with healthy controls. Higher urinary 
levels of the three complement proteins were associated with a chronic histopathological 
phenotype in patients with IgAN. We did not identify any correlations between serum CFH and 
MBL with eGFR or proteinuria (data not shown). However, significant inverse correlations 
between the three urinary complement proteins (CFH, MBL and C5b-9) and eGFR were 
observed in IgAN. Taken together, our findings identified a potential association between 
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increased urinary levels of complement proteins and chronic renal damage. Urinary excretion of 
the three complement proteins is closely associated with the degree of renal function. While this 
could suggest accelerated complement activation with increasing disease severity, it is more 
likely a reflection of sclerotic renal damage, such as glomerulosclerosis and tubular atrophy, 
rather than active glomerular disease.  
 
Recently, crescentic lesions have been added to the updated version of Oxford classification 
and biopsy reporting will provide a MEST-C score.19 IgAN patients with cellular or fibrocellular 
crescents were shown to be at risks of a poor renal outcome.18 In the present study, an 
elevation of both urinary CFH and MBL levels was observed in the patients with crescents 
formation (C1-2) compared to the patients without (C0). Further studies are necessary to assess 
the possible implications of this in relation to disease activity and complement activation. 
 
Previous studies have shown an association between urinary complement proteins and tubular 
damage markers, including β2-microglobulin, in IgAN as well as other types of proteinuric renal 
diseases.15,26 In line with this, we found significant correlations between the three complement 
proteins (CFH, MBL and C5b-9) in urine and the tubular damage markers, urinary RBP and α1-
MG, both known to be ligands to the endocytic receptor megalin.21-23 Similar correlations were 
observed for CKD patients. Based on these findings, we speculate that urinary excretion of 
these complement proteins may be associated with proximal tubule dysfunction, and possible 
reduced megalin activity. 
 
The source of urinary complement proteins remains unclear. Recent studies suggest that 
urinary CFH and MBL may derive from deposited CFH and MBL in renal tissue from patients 
with IgAN.12,14 Unfortunately, we did not have the opportunity to measure the renal deposition of 
these complement proteins in the patients. The urinary excretion of complement proteins did not 
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correlate with their respective levels in serum, but correlated negatively with eGFR and only 
weakly with proteinuria, which supports the notion that urinary complement proteins may not 
derive from the filtration of plasma proteins alone. It has been suggested that the kidney has the 
capacity to synthesize most of the complement components.27,28 Greater amounts of CFH 
transcript were observed in tubular fraction than in glomerular or medullar fractions of normal 
human kidney, and interferon-gamma has been shown to induce biosynthesis of CFH by human 
proximal tubular epithelial cells.29 Thus, it is possible that the urinary complement proteins, at 
least in part, may be derived from intrarenal synthesis, and excretion to the urinary space. 
 
There are some limitations in our study. Firstly, it was a single-center study with a single ethnic 
group and a limited number of patients. Secondly, this study is cross-sectional and does not 
allow us to evaluate disease progression in relation to serum or urinary complement protein 
levels. Thus, further studies are needed to evaluate if changes are associated with disease 
susceptibility or represent the consequence of such. It would definitely be interesting to carry out 
a study with follow-up, allowing assessment of the prognostic implications of our findings. 
Moreover, we did not measure all complement factors, and other complement proteins 
potentially involved in IgAN need to be examined.  
 
Conclusions 
In conclusion, our study suggests that increased urinary excretion of complement proteins in 
IgAN is related to chronic injury and proximal tubule dysfunction. This suggests caution using 
urinary complement components as markers of active glomerular disease. Further studies are 
important to clarify the pathophysiological mechanism underlying urinary complement excretion 
in IgAN. 
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Figure legends 
Figure 1. Serum CFH, MBL and C5b-9 levels in patients with IgAN or CKD, and healthy 
controls. (A, B) Serum CFH levels were significantly increased and MBL levels decreased in 
IgAN patients, including all subgroups, and in CKD patients compared with healthy controls. (C) 
Serum C5b-9 levels were significantly increased in patients with IgAN compared with healthy 
controls; the levels were significantly higher in IgAN patients of group 3 than in healthy controls. 
CFH, complement factor H; MBL, mannose-binding lectin; C5b-9, membrane attack complex; 
IgAN, IgA nephropathy; CKD, chronic kidney disease. Healthy controls, n = 20; CKD patients, n 
= 23; IgAN patients, n = 85; IgAN-Group 1, IgAN patients with M0E0S0T0, n = 20; IgAN-Group 
2, IgAN patients with M1E1S0-1T0-1, n = 25; IgAN-Group 3, IgAN patients with M1E1S0-1T2 or 
M0E0S1T1-2, n = 40. Each box plot represents the median and the 25th and 75th percentiles. 
Whiskers represent 1.5 times interquartile range. Differences among various groups were 
compared using Kruskal-Wallis test. The Bonferroni method was applied to correct for multiple 
comparisons. *P (vs. Healthy controls) < 0.01. 
 
 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Figure 2. Urinary CFH, MBL and C5b-9 levels in patients with IgAN or CKD, and healthy 
controls. (A) Urinary CFH levels were significantly increased in IgAN patients, including all 
subgroups, and in CKD patients compared with healthy controls; the levels were significantly 
higher in IgAN patients of group 3 than in group 1 and 2. (B) Urinary MBL levels were 
significantly increased in patients with IgAN, including all subgroups, compared with healthy 
controls; the levels were significantly higher in all IgAN patients and the subgroup 3 than in CKD 
patients. (C) Urinary C5b-9 levels were significantly increased in all IgAN patients, including 
subgroup 3, and in CKD patients compared with healthy controls. CFH, complement factor H; 
MBL, mannose-binding lectin; C5b-9, membrane attack complex; IgAN, IgA nephropathy; CKD, 
chronic kidney disease; Cr, creatinine. Healthy controls, n = 20; CKD patients, n = 23; IgAN 
patients, n = 85; IgAN-Group 1, IgAN patients with M0E0S0T0, n = 20; IgAN-Group 2, IgAN 
patients with M1E1S0-1T0-1, n = 25; IgAN-Group 3, IgAN patients with M1E1S0-1T2 or 
M0E0S1T1-2, n = 40. Each box plot represents the median and the 25th and 75th percentiles. 
Whiskers represent 1.5 times interquartile range. Differences among various groups were 
compared using Kruskal-Wallis test. The Bonferroni method was applied to correct for multiple 
comparisons. *P (vs. Healthy controls) < 0.01; #P (vs. CKD) < 0.01; §P (vs. IgAN-Group 1 and 2) 
< 0.001.  
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Figure 3. Correlations between urinary complement proteins and clinical parameters of 
patients with IgAN or CKD. (A) Urinary CFH, MBL, and C5b-9 levels correlated inversely with 
eGFR in patients with IgAN. (B) Urinary CFH levels significantly correlated with 24-hour urinary 
protein excretion in patients with IgAN whereas the levels of MBL and C5b-9 did not correlate 
with it. (C) No significant correlations were observed in CKD patients between eGFR and the 
levels of urinary CFH, MBL or C5b-9. (D) Urinary levels of CFH and MBL, but not C5b-9 
significantly correlated with 24-hour urinary protein excretion in CKD patients. IgAN, IgA 
nephropathy; CKD, chronic kidney disease; CFH, complement factor H; MBL, mannose-binding 
lectin; C5b-9, membrane attack complex; eGFR, estimated glomerular filtration rate. The ratios 
of urinary CFH, MBL or C5b-9 to creatinine (Cr) were presented using logarithmic scale to make 
these conform or close to a normal distribution. The correlation among various parameters was 
analysed using Pearson or Spearman’s coefficient.  
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Figure 4. Correlations between urinary excretion of complement proteins and tubular 
damage markers, i.e., established megalin ligands: RBP and α1-MG, in patients with IgAN. 
The urinary excretion of RBP (A-C) and α1-MG (D-F) significantly and positively correlated with 
the urinary excretion of CFH, MBL and C5b-9 in patients with IgAN. IgAN, IgA nephropathy; 
RBP, retinol-binding protein; α1-MG, α1-microglobulin; CFH, complement factor H; MBL, 
mannose-binding lectin; C5b-9, membrane attack complex. The ratios of urinary CFH, MBL or 
C5b-9 to creatinine (Cr) were presented using logarithmic scale to make these conform or close 
to a normal distribution. The correlation among various parameters was analysed using 
Spearman’scoefficient. 
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CKD, chronic kidney disease; IgAN, IgA nephropathy; MAP, mean arterial pressure; eGFR, estimated glomerular filtration rate; RAS, renin-
angiotensin system; group 1, patients with M0E0S0T0; group 2, patients with M1E1S0-1T0-1; group 3, patients with M1E1S0-1T2 or M0E0S1T1-2; 
patients with focal segmental glomerulosclerosis or hypertensive nephrosclerosis were included in CKD controls group. Values were described by 
absolute frequencies and percentages for categorical variables and median (lower and upper quartiles) for quantitative variables.  Statistical 
analysis was done using Chi-square test (categorical variables) or Kruskal-Wallis test (quantitative variables) for comparisons between groups. The 
Bonferroni test was used for multiple comparison correction and the level of significance was of P < 0.017 or P < 0.005. *P < 0.005 vs. Healthy 
controls;
 §
P < 0.017 vs. CKD;   #P < 0.005 vs. CKD; †P < 0.005 vs. IgAN-Group 1; ‡P < 0.005 vs. IgAN-Group 2.  
 
Variables 
Healthy controls 
n = 20 
CKD 
n = 23 
IgAN 
n = 85 
IgAN-Group 1 
n = 20 
IgAN-Group 2 
n = 25 
IgAN-Group 3 
n = 40 
Age (year) 35 (27.5, 44) 44 (33, 51) 38 (27, 47) 36.5 (22, 46.3) 32 (24, 51) 39 (29, 47) 
Gender, male, n (%) 11 (55.0) 14 (60.9) 50 (58.8) 12 (60.0) 11 (44.0) 27 (67.5) 
MAP (mmHg) 89 (86, 92) 117 (96, 137)* 101 (93, 113)* 96 (90, 101)* 98 (92, 109)* 107 (99, 116)*,†  
Serum creatinine 
(μmol/L) 
62 (54, 71.8) 142 (105, 156)* 94 (69.5, 157)*
§
 64.5 (55.3, 80.8)
# 78 (63.5, 93)*,# 166 (108.5, 226.5)*,†, ‡ 
eGFR 
(ml/min/1.73m2) 
117.4 (107.6, 123.7) 51 (41.8, 64.3)* 71.3 (43.3, 111.6)*
§
 117.9 (92.1, 129.5)
# 94 (71.9, 115.3)*,# 40 (30.5, 60.3)*,†,‡ 
24-hour urinary 
protein (g) 
0.04 (0.01, 0.05) 1.6 (0.97, 3.43)* 2.89 (1.47, 4.93)* 1.86 (0.61, 3.69)* 2.47 (1.34, 5.29)* 3.46 (1.72, 5.24)* 
Treated with RAS 
blocker, n (%) 
-- 7 (30.4) 18 (21.2) 3 (15.0) 8 (32.0) 7 (17.5) 
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Table 2. Histopathological characteristics of IgAN patients in different groups. 
 
 
 
 
 
 
 
 
Values were described by absolute frequencies and percentages for categorical variables. 
IgAN, IgA nephropathy; group 1, patients with M0E0S0T0; group 2, patients with M1E1S0-1T0-
1; group 3, patients with M1E1S0-1T2 or M0E0S1T1-2. Statistical analysis was done using Chi-
square test for comparisons between groups. The Bonferroni test was used for multiple 
comparison correction and the level of significance was of P < 0.017. *P < 0.017 vs. Group 1.  
 
 
Group 1 
n = 20 
Group 2 
n = 25 
Group 3 
n = 40 
P Value 
Crescent scores    0.01 
C 0, n (%) 19 (95) 10 (40) 22 (55)  
C 1-2, n (%) 1 (5) 15 (60)* 18 (45)*  
Glomerular 
deposition of C3 
   0.05 
Score 0, n (%) 7 (35) 8 (32) 11 (27.5)  
Score 1, n (%) 9 (45) 7 (28) 6 (15)  
Score 2-3, n (%) 4 (20) 10 (40) 23 (57.5)  
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Table 3. Correlations of urinary complement proteins with RBP and α1-MG excretion in 
patients with CKD. 
 
CFH, complement factor H; MBL, mannose-binding lectin; C5b-9, membrane attack complex; 
CKD, chronic kidney disease; RBP, retinol-binding protein; α1-MG, α1-microglobulin; The ratios 
of urinary CFH, MBL or C5b-9 to creatinine (Cr) were presented using logarithmic scale to make 
these conform or close to a normal distribution. The correlation among various parameters was 
analysed using Pearson or Spearman’s coefficient. 
 Log10 (CFH/Cr) 
n = 23 
Log10 (MBL/Cr) 
n = 23 
Log10 (C5b-9/Cr) 
n = 23 
 r P r P r P 
Urinary RBP/Cr (µg/mg) 0.76 <0.001 0.57 0.004 0.55 0.006 
Urinary α1-MG/Cr (µg/mg) 0.64 0.001 0.61 0.002 0.55 0.007 
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